Cite
HARVARD Citation
Urup, T. et al. (2020). Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Molecular oncology. 14 (5), pp. 964-973. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Urup, T. et al. (2020). Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Molecular oncology. 14 (5), pp. 964-973. [Online].